Aristotle Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $76.7M | Sell |
1,463,518
-64,498
| -4% | -$3.41M | 0.16% | 82 |
|
|
2026
Q1 | $84.3M | Sell |
1,528,016
-33,127
| -2% | -$1.8M | 0.18% | 78 |
|
|
2025
Q4 | $76.6M | Sell |
1,561,143
-47,038
| -3% | -$2.19M | 0.15% | 81 |
|
|
2025
Q3 | $69.4M | Sell |
1,608,181
-22,871
| -1% | -$893K | 0.13% | 84 |
|
|
2025
Q2 | $62.6M | Sell |
1,631,052
-44,408
| -3% | -$1.7M | 0.12% | 91 |
|
|
2025
Q1 | $64.9M | Buy |
1,675,460
+74,140
| +5% | +$2.71M | 0.13% | 82 |
|
|
2024
Q4 | $54.2M | Sell |
1,601,320
-187,055
| -10% | -$6.73M | 0.1% | 98 |
|
|
2024
Q3 | $73.1M | Sell |
1,788,375
-4,428
| -0.2% | -$181K | 0.13% | 91 |
|
|
2024
Q2 | $69M | Buy |
1,792,803
+28,341
| +2% | +$1.19M | 0.13% | 83 |
|
|
2024
Q1 | $75.6M | Buy |
1,764,462
+187
| +0% | +$7.71K | 0.14% | 77 |
|
|
2023
Q4 | $65.4M | Buy |
1,764,275
+31,171
| +2% | +$1.12M | 0.13% | 85 |
|
|
2023
Q3 | $62.8M | Buy |
1,733,104
+17,106
| +1% | +$607K | 0.14% | 79 |
|
|
2023
Q2 | $61.2M | Buy |
1,715,998
+38,991
| +2% | +$1.4M | 0.12% | 90 |
|
|
2023
Q1 | $59.7M | Buy |
1,677,007
+91,975
| +6% | +$3.22M | 0.13% | 89 |
|
|
2022
Q4 | $55.7M | Buy |
1,585,032
+177,162
| +13% | +$5.9M | 0.12% | 86 |
|
|
2022
Q3 | $41.4M | Sell |
1,407,870
-13,205
| -0.9% | -$500K | 0.09% | 101 |
|
|
2022
Q2 | $77.3M | Buy |
1,421,075
+31,255
| +2% | +$1.73M | 0.16% | 58 |
|
|
2022
Q1 | $75.7M | Buy |
1,389,820
+59,688
| +4% | +$3.24M | 0.14% | 60 |
|
|
2021
Q4 | $73.3M | Buy |
1,330,132
+49,646
| +4% | +$2.58M | 0.12% | 68 |
|
|
2021
Q3 | $61.2M | Buy |
1,280,486
+63,613
| +5% | +$3.2M | 0.12% | 73 |
|
|
2021
Q2 | $60.6M | Buy |
1,216,873
+240,899
| +25% | +$11.6M | 0.12% | 71 |
|
|
2021
Q1 | $43.5M | Buy |
+975,974
| New | +$44.3M | 0.09% | 78 |
|
|
2018
Q2 | – | Sell |
-4,999
| Closed | -$244K | – | 185 |
|
|
2018
Q1 | $244K | Buy |
4,999
+18
| +0.4% | +$838 | ﹤0.01% | 170 |
|
|
2017
Q4 | $221K | Sell |
4,981
-26
| -0.5% | -$1.2K | ﹤0.01% | 175 |
|
|
2017
Q3 | $254K | Buy |
+5,007
| New | +$254K | ﹤0.01% | 140 |
|
|
2015
Q2 | – | Sell |
-3,570
| Closed | -$206K | – | 133 |
|
|
2015
Q1 | $206K | Sell |
3,570
-800
| -18% | -$45.9K | ﹤0.01% | 133 |
|
|
2014
Q4 | $233K | Hold |
4,370
| – | – | ﹤0.01% | 135 |
|
|
2014
Q3 | $251K | Hold |
4,370
| – | – | ﹤0.01% | 133 |
|
|
2014
Q2 | $292K | Hold |
4,370
| – | – | ﹤0.01% | 146 |
|
|
2014
Q1 | $292K | Hold |
4,370
| – | – | ﹤0.01% | 126 |
|
|
2013
Q4 | $292K | Hold |
4,370
| – | – | ﹤0.01% | 126 |
|
|
2013
Q3 | $274K | Hold |
4,370
| – | – | 0.01% | 127 |
|
|
2013
Q2 | $273K | Buy |
+4,370
| New | +$277K | 0.01% | 123 |
|
Other funds holding GSK
JEST
Aristotle Capital Management's GSK Position: Q2 2026 in Review
Aristotle Capital Management reduced its GSK (GSK) stake by 4.2% in Q2 2026, selling an estimated $3.41M and leaving 1,463,518 shares worth $76.7M. The position accounts for 0.16% of the portfolio, ranked #82.
Aristotle Capital Management first reported a position in GSK in Q2 2013 and has held it in 33 quarters since. The position peaked at $84.3M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Aristotle Capital Management held 1,463,518 shares of GSK worth $76.7M as of Q2 2026.
- Aristotle Capital Management sold 64,498 GSK shares in Q2 2026, an estimated $3.41M.
- GSK made up 0.16% of Aristotle Capital Management's portfolio in Q2 2026, its #82 holding.
- Aristotle Capital Management first reported a position in GSK in Q2 2013 and has held it in 33 quarters since.
- Aristotle Capital Management's GSK position peaked at $84.3M in Q1 2026.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Aristotle Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.